Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

NCT06524739 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision, not for safety reasons.

Conditions

Post-COVID Postural Orthostatic Tachycardia Syndrome

Interventions

BIOLOGICAL: IgPro20
BIOLOGICAL: Placebo

Sponsor

CSL Behring